In the Review article “Pimavanserin: A novel therapeutic option for Parkinson disease psychosis” by T. Hawkins and B.D. Berman,1 there are 2 minor errors. The last sentence in the third paragraph under “Development of pimavanserin” should have read “In addition, pimavanserin did not affect motor symptom severity and led to significant decreases in caregiver burden and improvements in nighttime sleep and daytime wakefulness.” The second-to-last sentence under “Prescribing information” should read “In the positive phase 3 trial of pimavanserin detailed above, there were 3 deaths; 2 in the treatment group and 1 in the placebo group.” The authors regret the errors.
- © 2017 American Academy of Neurology
REFERENCE
- 1.↵
The Nerve!: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.